Industry Seeks Flexibility, Clarity On US FDA Clinical Trial Diversity Action Plan Requirements

Draft guidance recommendations on setting enrollment goals lead PhRMA and BIO to seek assurances of FDA flexibility absent reliable disease prevalence data.